Timothy Keutzer has sold SPRO and made no open-market buys since Feb 2024

Timothy Keutzer is the Chief Operating Officer (COO) of Spero Therapeutics, Inc. (NASDAQ: SPRO), a clinical-stage biopharmaceutical company focused on infectious diseases.( Appointed COO effective February 1, 2023, he previously served as Chief Development Officer from June 2019 to February 2023 and Senior Vice President of Development from September 2015 to June 2019.( With over 30 years in the pharmaceutical industry, Keutzer brings expertise across functional and therapeutic areas.(

Before joining Spero, Keutzer was Vice President of Program and Portfolio Management at Cubist Pharmaceuticals from May 2014 to July 2015, where he led the ceftolozane/tazobactam program from Phase 1 to FDA approval in December 2014.( His earlier roles include preclinical PK/PD and clinical operations at Genetics Institute, global strategic marketing and program management at Wyeth Pharmaceuticals, and starting in contract toxicology labs.( He holds a bachelor's degree from the University of Kentucky.( Recently, on February 6, 2026, Keutzer sold 18,652 shares at $2.36 to cover tax obligations from RSU vesting, retaining 742,506 shares.(

Written by Perplexity from public sources.